CN114302879A - 选择性雌激素受体降解剂 - Google Patents

选择性雌激素受体降解剂 Download PDF

Info

Publication number
CN114302879A
CN114302879A CN202080053315.6A CN202080053315A CN114302879A CN 114302879 A CN114302879 A CN 114302879A CN 202080053315 A CN202080053315 A CN 202080053315A CN 114302879 A CN114302879 A CN 114302879A
Authority
CN
China
Prior art keywords
formula
compound
cancer
less
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080053315.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·K·帕尔
B·萨曼塔
J·D·阿拉德耶
S·P·帕萨克
K·D·普拉贾帕蒂
B·M·潘查
T·R·奇图里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Publication of CN114302879A publication Critical patent/CN114302879A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080053315.6A 2019-07-22 2020-07-22 选择性雌激素受体降解剂 Pending CN114302879A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
CN114302879A true CN114302879A (zh) 2022-04-08

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080053315.6A Pending CN114302879A (zh) 2019-07-22 2020-07-22 选择性雌激素受体降解剂

Country Status (15)

Country Link
US (2) US11014915B2 (https=)
EP (1) EP4003525A1 (https=)
JP (1) JP2022541938A (https=)
KR (1) KR20220046586A (https=)
CN (1) CN114302879A (https=)
AU (1) AU2020317099A1 (https=)
BR (1) BR112022001285A2 (https=)
CA (1) CA3148592A1 (https=)
CL (1) CL2022000156A1 (https=)
IL (1) IL290036A (https=)
MX (1) MX2022001013A (https=)
PE (1) PE20221588A1 (https=)
PH (1) PH12022550182A1 (https=)
WO (1) WO2021014386A1 (https=)
ZA (1) ZA202201157B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638870A (zh) * 2018-09-07 2021-04-09 赛诺菲 用于制备6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127054B (zh) 2019-07-22 2024-04-09 勃林格殷格翰国际有限公司 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제
CA3243621A1 (en) * 2022-02-01 2023-08-10 Eli Lilly And Company METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS
CN119176799B (zh) * 2024-09-19 2025-10-03 晨伫(杭州)生物科技有限责任公司 色烯衍生物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090829A1 (en) * 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CN105451735A (zh) * 2013-06-19 2016-03-30 西拉根制药公司 氮杂环丁烷雌激素受体调节剂和其用途
CN107406433A (zh) * 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
CN108699021A (zh) * 2015-10-27 2018-10-23 太阳医药高级研究有限公司 新的杂环抗雌激素

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
EP0470310B1 (en) 1990-08-09 1995-11-29 Council of Scientific and Industrial Research Novel benzopyrans and process for their production
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090829A1 (en) * 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CN105451735A (zh) * 2013-06-19 2016-03-30 西拉根制药公司 氮杂环丁烷雌激素受体调节剂和其用途
CN107406433A (zh) * 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
CN108699021A (zh) * 2015-10-27 2018-10-23 太阳医药高级研究有限公司 新的杂环抗雌激素

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638870A (zh) * 2018-09-07 2021-04-09 赛诺菲 用于制备6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的方法
CN112638870B (zh) * 2018-09-07 2025-04-25 赛诺菲 用于制备6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的方法

Also Published As

Publication number Publication date
ZA202201157B (en) 2023-07-26
CL2022000156A1 (es) 2022-11-18
WO2021014386A1 (en) 2021-01-28
PE20221588A1 (es) 2022-10-10
JP2022541938A (ja) 2022-09-28
PH12022550182A1 (en) 2022-11-14
EP4003525A1 (en) 2022-06-01
BR112022001285A2 (pt) 2022-03-22
KR20220046586A (ko) 2022-04-14
CA3148592A1 (en) 2021-01-28
US20210024504A1 (en) 2021-01-28
US11014915B2 (en) 2021-05-25
AU2020317099A1 (en) 2022-02-24
IL290036A (en) 2022-03-01
US20210261534A1 (en) 2021-08-26
MX2022001013A (es) 2022-02-22

Similar Documents

Publication Publication Date Title
CN114302879A (zh) 选择性雌激素受体降解剂
US11672785B2 (en) Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
US9115091B2 (en) Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
TW201710253A (zh) 抗雌激素化合物
KR20140107371A (ko) 6,7-디히드로-5h-벤조[7]아눌렌 유도체, 그의 제조 방법, 상기 6,7-디히드로-5h-벤조[7]아눌렌 유도체를 함유하는 제약 제제, 및 약물을 제조하기 위한 그의 용도
Bai et al. Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities
WO2011129837A1 (en) Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer
US7632963B2 (en) Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
NZ294176A (en) Medicaments containing tamoxifen derivatives and analogues and a naphthyl derivative; a method of minimizing the uterotrophic effect of tamoxifen and its analogues
WO2024042163A1 (en) Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2004031125A1 (ja) スピロ化合物、それを含有する医薬組成物及び該化合物の中間体
JP2025531033A (ja) 新規の置換２－カルボニル－ベンゾチオフェン－６－カルボン酸誘導体、それらの調製のためのプロセス及びその治療的使用
CN119790048A (zh) 新颖的取代的四氢异喹啉-6-甲酸衍生物、用于其制备的方法及其治疗用途
JP5054882B2 (ja) テトラヒドロベンズフルオレン誘導体
RU2855858C2 (ru) ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
US20250197420A1 (en) Macrocyclic compounds, compositions, and methods of using thereof
Vedavi et al. Exploration of new 5-chloro-7-iodo quinoline core analogues as anti-pancreatic cancer hits targeting MIA PaCa-2: EGFR inhibition
JP2025523065A (ja) アゾポドフィロトキシン誘導体ｓｕ０５６のエナンチオマー
CN115819407A (zh) 一种Ensitrelvir类似物及其制备方法和抗新冠用途
KR20210134306A (ko) 아크릴-함유 핵 수출 조절제들 및 이들의 용도들
HK1124337A (en) Nuclear receptor binding agents
WO2016022325A1 (en) Novel triarylethylene compounds and methods using same
HK1204960B (zh) 高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类及其用途
HK1141519B (en) Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220408

WD01 Invention patent application deemed withdrawn after publication